American Association for Cancer Research
Browse
crc-22-0415-s11.pdf (746.84 kB)

Fig. S11 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Download (746.84 kB)
journal contribution
posted on 2023-06-13, 14:20 authored by Kazunori Aoki, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi, Etsuko Fujii, Takashi Nishizawa, Hironori Fukuda, Kana Ohashi, Kosuke Arai, Yukihiro Mizoguchi, Yukihiro Yoshida, Shun-ichi Watanabe, Makiko Yamashita, Shigehisa Kitano, Hiromi Sakamoto, Yuki Nagata, Risa Mitsumori, Kouichi Ozaki, Shumpei Niida, Yae Kanai, Akiyoshi Hirayama, Tomoyoshi Soga, Toru Maruyama, Keisuke Tsukada, Nami Yabuki, Mei Shimada, Takehisa Kitazawa, Osamu Natori, Noriaki Sawada, Atsuhiko Kato, Teruhiko Yoshida, Kazuki Yasuda, Hideaki Mizuno, Hiroyuki Tsunoda, Atsushi Ochiai

Percentage of PD-1+ CD8 T+ and PD-L1+ CD8 T+ cells in respective immune subtypes. (a, b) Data were presented as a percentage of PD-1+ cells (a) and PD-L1+ cells (b) per indicated CD8+ T cell subset in LUAD and LUSQ. % naïve CD8; percentage of PD-1+ or PD-L1+ naïve CD8+ T cell subset per total of naïve CD8+ T cells. % CM CD8; percentage of PD-1+ or PD-L1+ CM CD8+ T cell subset per total of CM CD8+ T cells. % EM CD8; percentage of PD-1+ or PD-L1+ EM CD8+ T cell subset per total of EM CD8+ T cells. % EMRA CD8; percentage of PD-1+ or PD-L1+ EMRA CD8+ T cell subset per total of EMRA CD8+ T cells. ns; not significant. * p<0.05. **P<0.01.

Funding

Japan Agency for Medical Research and Development (AMED)

National Cancer Center Japan (NCC)

MEXT | Japan Society for the Promotion of Science (JSPS)

History

ARTICLE ABSTRACT

The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC